Melanoma/Skin Cancer News

Pembrolizumab monotherapy appeared to be effective and safe as first-line treatment for patients with unresectable cutaneous squamous cell carcinoma, according to results of a phase 2 study published in Journal of Clinical Oncology.

City of Hope announced it has reached an agreement with Australia-based biotech Chimeric Therapeutics.

The 31-gene expression profile test demonstrated consistent sensitivity in identifying patients with melanoma at risk for recurrence or distant metastasis, according to a study.

Igor Puzanov, MD, MSCI, FACP, has been promoted to senior vice president of clinical investigation at Roswell Park Comprehensive Cancer Center.

A “sandwich” approach to melanoma treatment consisting of immunotherapy between two targeted therapy courses showed a trend toward improved total PFS, according to study results presented at ESMO Virtual Congress 2020.

The addition of spartalizumab to dabrafenib and trametinib failed to prolong PFS among patients with BRAF-mutated advanced melanoma, according to results from the randomized phase 3 COMBI-i trial presented at ESMO Virtual Congress 2020.

The European Society for Medical Oncology announced the recipients of this year’s ESMO Awards.

The combination of mogamulizumab and topical steroids conferred favorable outcomes to patients with previously treated cutaneous T-cell lymphoma, according to study results presented at Society of Hematologic Oncology Annual Meeting.

Two gene expression profile tests for cutaneous melanoma often failed to accurately identify recurrent stage I disease, according to a study.

Fox Chase Cancer Center announced several faculty appointments.